First Hurdle Cleared for Generic Market Entry

Global generic pharmaceutical company Teva Pharmaceuticals USA, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its canagliflozin generic drug application (ANDA) 210451. Tentative approval indicates that the drug meets bioequivalence and manufacturing quality standards, but final marketing authorization is pending due to patent and exclusivity disputes. This means that the product cannot be launched on the market until the original drug's patent expires or legal proceedings are resolved. However, Teva has strategically positioned itself to quickly supply generic products to the market upon patent expiration.

Original Patent Barrier and Judicial License Agreement

Mitsubishi Tanabe Pharma Corporation, which holds the substance patent for canagliflozin, and Janssen, which has exclusive marketing rights in the United States, have defended against Teva with patent infringement lawsuits. In March 2021, the U.S. District Court for the District of New Jersey ruled in favor of the original drug manufacturer, blocking early entry by generic manufacturers. As a result, Teva and other generic companies are restricted from commercializing their products in the United States until July 14, 2027, when the patent expires. Therefore, this tentative approval can be seen as a long-term regulatory step to penetrate the market immediately upon patent expiration, rather than contributing to short-term sales.

Clinical Value and Indications of SGLT2 Inhibitor Class

Canagliflozin is an innovative diabetes treatment drug in the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, which inhibits the reabsorption of glucose in the kidneys and excretes glucose in the urine. It not only lowers blood sugar in type 2 diabetes but also slows the progression of chronic kidney disease and significantly reduces the risk of major adverse cardiovascular events, providing multiple indications. These multiple benefits provide essential treatment options for patients with diabetes and cardiovascular or renal disease, significantly improving their quality of life. The introduction of generic drugs will lower drug prices, allowing more patients to benefit from the latest diabetes treatments.

Competitive Dynamics and Commercial Impact of Blockbuster Market

The global SGLT2 inhibitor market, to which canagliflozin belongs, is estimated at approximately $16.8 billion in 2024 and is projected to expand to $28.9 billion by 2033. The market is currently dominated by AstraZeneca's Farxiga and Eli Lilly and Boehringer Ingelheim's Jardiance, which together account for the majority of the market share. The original product, Invokana, is expected to generate approximately $835 million in sales in 2024 and $870 million in 2025, but its market share is declining. In this environment, the launch of Teva's high-quality generic drug will put pressure on the price of the original drug and trigger price competition with existing leading products, shaking up the market share landscape.